System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Tateaki Naito is an expert in Oncology at Shizuoka Cancer Center (Japan). As of October 2026, ScienceLeadR ranks Tateaki Naito in the top 1% of experts worldwide for Cachexia, Bronchial Neoplasms and Thoracic Neoplasms. Tateaki Naito has authored 349 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 978 (community average: 125). How the SLR is computed.

LeadR Profile

Tateaki Naito Shizuoka Cancer Center Japan
978 ScienceLeadR Reputation 978

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Public Health - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr. Tateaki Naito, MD, PhD, is the Director of the Cancer Supportive Care Center and Chief Physician of Thoracic Oncology at Shizuoka Cancer Center. He graduated from Hamamatsu University School of Medicine in 1997 and has over twenty years of experience in thoracic oncology, cancer cachexia, and cancer supportive care. In addition, he is a Clinical Professor at St. Luke's International University, Graduate School of Nursing Science. Dr. Naito has been a board member of the Multinational Association of Supportive Care in Cancer (MASCC) and the Japanese Association of Supportive Care in Cancer (JASCC) since 2024. He plays leadership roles in the Nutrition & Cachexia Study Group of both JASCC and MASCC. His research involves numerous clinical trials of pharmacotherapies and non-pharmacological multimodal interventions for thoracic cancer and cancer cachexia. Furthermore, he holds key editorial positions as the Editor-in-Chief of Thoracic Cancer, Associate Editor of the Asia-Pacific Journal of Oncology Nursing (APJON), and the Journal of Cachexia, Sarcopenia, and Muscle (JCSM).

Organizations

Career arc: 2003 - 2026
Source: PubMed

Shizuoka Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 349

Citations

Citations: 7 125 1st author: 17 Last author: 15 Unique author: 11

Main journals

J Clin Oncol 25
Lung Cancer 20
Ann Oncol 18
Int J Clin Oncol 16
Invest New Drugs 16

Best Journals

Ann Oncol 8
J Clin Oncol 6
Eur Heart J 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
PMID 42723143 — cells, lung, neoplasms, carcinoma, non-small-cell lung, rehabilitation, drug therapy, lung neoplasms, chemotherapy, adjuvant, small cell lung carcinoma, chemotherapy		Int J Cancer20260
Feasibility and safety of combined touch care and aromatherapy in hospitalized patients with thoracic malignancies: A prospective single-arm study.
PMID 42376613 — touch, safety, aromatherapy, drug-related side effects and adverse reactions		Asia Pac J Oncol Nurs20260
Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.
PMID 42374134 — depression, quality of life, activities of daily living, pain, neoplasms, fatigue, body weight, weight loss, therapeutics, cachexia, sarcopenia		J Cachexia Sarcopenia Muscle20261
Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.
PMID 42228208 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, weight loss, therapeutics, palliative care, cachexia, chemotherapy		Support Care Cancer20260
Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Institution Retrospective Study.
PMID 42067397 — cells, lung, pleural effusion, progression-free survival, docetaxel, retrospective studies, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, edema, pleural effusion, malignant		Thorac Cancer20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 1 2
Phase 2 2
Phase 3 2

By status:

Completed 4
Recruiting 2

By type:

Interventional 6

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 4

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851 — pharmaceutical preparations, dexamethasone, cyclophosphamide, receptors, serotonin, 5-ht3, neoplasms, gastric inhibitory polypeptide, drug therapy, vomiting, drug-related side effects and adverse reactions, antiemetics, nausea, incretins, anthracyclines, therapeutics, chemotherapy		Phase 2Recruiting2025
A Study of First Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C Mutant Non small Cell Lung Cancer
NCT06119581 — cells, carcinoma, bronchogenic, pemetrexed, lung, thoracic neoplasms, respiratory tract diseases, respiratory tract neoplasms, antineoplastic agents, neoplasms, carcinoma, non-small-cell lung, drug therapy, neoplastic processes, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, neoplasms by site, therapeutics, lung diseases, pathologic processes, carboplatin, mutation, bronchial neoplasms, chemotherapy, carcinoma		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS